Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why
US-based multinational pharmaceutical giant Eli Lilly & Co., on Tuesday, 17 June 2025, announced its plans to acquire gene-editing biotech firm Verve Therapeutics Inc. for $1.3 billion as the big pharma company eyes expansion in experimental medicine for long-term growth, reported the news agency Bloomberg.
According to the agency report, Eli Lilly & Co. will pay up to $13.50 per share for the acquisition deal. The breakdown of the deal will be that Eli Lilly & Co. will pay $10.50 per share in cash as well as a non-tradeable contingent value right that entitles the holder to receive as much as $3 extra per share.
The transaction is expected to close in the third quarter of the current year, reported the news agency, citing the company.
Verve Therapeutics shares skyrocketed 75.12% to $10.99 at the US stock market open at 9:38 a.m. (EDT), compared to $6.27 at the previous market close. However, pharma major Eli Lilly & Co. shares are trading 1.45% lower on Wall Street at $795.84 as of 9:40 a.m. (EDT), compared to $807.58 at the previous stock market close.
The US big pharma company Eli Lilly & Co.'s revenues are centred around its iconic weight-loss drug, Zepbound, as the company prepares for the medicine's patent to expire.
The news agency reported that the company has been able to target experimental medicines that are still far from the market.
In this area, price tags are usually smaller than for therapies that have already undergone multiple patient trials. The long-term return on such early-stage deals can be far larger.
In January 2025, Eli Lilly & Co. agreed to pay up to $2.5 billion for a cancer medicine which was being tested by Scorpion Therapeutics Inc., as per the agency report. Further in May, the company announced a plan to buy SiteOne Therapeutics Inc., a biotech firm developing pain medicines, for nearly $1 billion.
Eli Lilly & Co. was reportedly in collaboration with Verve Therapeutics on its experimental gene-editing program for reducing lipoprotein, which is a risk factor for plaque buildup in human arteries.
This acquisition deal will give Eli Lilly & Co. full control of the program, as the company shows confidence in its gene editing drug, which is a cutting-edge technology in the market, according to the report.
However, this technology has struggled to attract investors recently, in part because it's expensive to make and aimed at providing one-time cures for rare diseases that may not be lucrative.
Verve is a rare example of a gene editing company targeting a disease that affects a large population and offering better commercial prospects. Its approach, which uses tiny balls of fat to deliver the treatment, is less expensive to make than other gene therapies.
Ruth Gimeno, the Vice President for diabetes and metabolic research and development at Eli Lilly & Co., told the news agency that the experimental therapy could be the first to edit genes inside a living body that's targeted to a broad population of patients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
12 minutes ago
- Time of India
Toy company challenges Trump tariffs at US Supreme Court; claims misuse of emergency powers; seeks urgent ruling
This is a representative AI image An Illinois-based toy maker, Learning Resources Inc., has taken its tariff battle to the US Supreme Court, urging the justices to swiftly rule on the legality of former President Donald Trump's trade tariffs. In legal documents, the company emphasised the urgency, citing "the tariffs' massive impact on virtually every business and consumer across the Nation, and the unremitting whiplash caused by the unfettered tariffing power the President claims." The company contends that Trump overstepped his authority by using an emergency powers law to impose tariffs without congressional approval. It filed the appeal in a bid to bypass ongoing proceedings in lower courts. Despite securing an initial lower court victory, the ruling remains suspended whilst an appeals court evaluates a similar decision that more broadly challenges Trump's tariffs. Currently, Trump maintains authority to collect tariffs under emergency powers legislation, with arguments scheduled for late July. The Supreme Court traditionally avoids cases before appeals courts reach decisions, reducing the likelihood of granting the expedited hearing requested by the company. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 임플란트, 지금 시작하세요 [자세히 보기] 임플란트 더 알아보기 Undo Learning Resources CEO Rick Woldenberg highlighted the current impact of tariffs and uncertainty, particularly concerning the approaching back-to-school and holiday periods, which typically generate their highest annual sales. "All the people that are raising their prices are doing it with a sense of dread," Woldenberg told The Associated Press. But, "we do not have a choice. We absolutely do not have a choice," he added. The company's legal representatives proposed scheduling arguments for late summer or early autumn. The Trump administration's defence maintains that emergency powers legislation authorises presidential control over imports during national emergencies, considering the persistent trade deficit as such an emergency. Trump presents tariffs as mechanisms to encourage domestic manufacturing, generate Treasury revenue, and negotiate more advantageous international trade agreements. Woldenberg described investing substantial resources into diversifying his company's supply chain, whilst acknowledging the process as lengthy and unpredictable. "I think that our case raises uniquely important questions that this administration won't accept unless the Supreme Court rules on them," he said. The family-owned enterprise, located in Vernon Hills, Illinois, produces items including the Pretend & Play Calculator Cash Register for $43.99 and Botley the Coding Robot for $57.99.
Time of India
16 minutes ago
- Time of India
Cachar bizman held for Rs 25cr GST evasion through fake ITC claims
Silchar: State GST department's Silchar unit has arrested a Cachar-based businessman for allegedly evading goods and services tax (GST) to the tune of Rs 25 crore through fake billing and fraudulent input tax credit (ITC) claims. The accused, Ishak Ahmed, listed as the director of Khushi Digital Payment Private Limited, was arrested following a raid at his business premises in Pailapool, Cachar. The raid was carried out based on inputs received from the department's Guwahati headquarters. Officials on Tuesday said documents and computers were seized during the operation. Ahmed, a resident of Alipur in the district, was taken into custody after he failed to produce valid documents for business transactions estimated to be worth Rs 100 crore. "We had specific inputs that Rs 15 crore worth of fake ITC was availed, and Rs 10 crore was passed on to other states — amounting to a total tax evasion of Rs 25 crore," said Ronit Roy, assistant commissioner of state tax on Tuesday. "Under Section 69 of the CGST Act, 2017, we are empowered to arrest individuals involved in evasion above Rs 5 crore," he added. Roy said Ahmed was summoned to produce receipts and transaction-related documents. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo "We deferred the hearing twice. On June 14, during the second hearing, he submitted documents that appeared forged. He claimed that a chartered accountant based in Delhi held the original papers and requested two more days, but even after three days, he failed to submit them," Roy told the media. Officials also found discrepancies in the company's directorship. While Ahmed claimed that ownership had changed hands last year, one of the listed directors denied involvement and has lodged a police complaint against him, alleging misuse of identity. Manjit Kumar Borah, joint commissioner of state tax, confirmed the arrest, saying "Following legal procedures, he was arrested and produced before the court. He has been remanded to 14 days of judicial custody. This is one of the major cases of GST fraud in the region through fake ITC claims." Sources in the department said that more arrests may follow as the investigation progresses, indicating that Ahmed may be part of a larger network involved in tax fraud.
Deccan Herald
16 minutes ago
- Deccan Herald
Fungi added to dirty diaper before it is thrown away
Could baby poop and fungi work together to tackle landfill waste? That's the idea behind a new product launched by an Austin, Texas-based startup that sells disposable diapers paired with fungi intended to break down the of Hiro Technologies' MycoDigestible Diapers comes with a packet of fungi to be added to the dirty diaper before it is thrown in the trash. After a week or two, the fungi are activated by moisture from feces, urine and the environment to begin the process of diapers contribute significantly to landfill waste. An estimated 4 million tons of diapers were disposed of in the United States in 2018, with no significant recycling or composting, according to the Environmental Protection Agency. Diapers take hundreds of years to naturally break down. That means the very first disposable diaper ever used is still in a landfill tackle this, Hiro Technologies turned to fungi. These organisms - which include mushrooms, molds, yeasts and mildew - derive nutrients from decomposing organic matter. In 2011, Yale University researchers discovered a type of fungus in Ecuador that can feed on polyurethane, a common polymer in plastic products. They figured the fungus, Pestalotiopsis microspora, would be capable of surviving on plastic in environments lacking oxygen, like Technologies co-founder Tero Isokauppila, a Finnish entrepreneur who also founded medicinal mushroom company Four Sigmatic, said there are more than 100 species of fungi now known to break down plastics."Many, many moons ago, fungi evolved to break down trees, especially this hard-to-break-down compound in trees called lignin. ... Its carbon backbone is very similar to the carbon backbone of plastics because essentially they're made out of the same thing," Isokauppila sealed jars at Hiro Technologies' lab show the stages of decomposition of a treated diaper over time. By nine months, the product appears as black soil - "just digested plastic and essentially earth," Isokauppila company says it needs to do more research to find out how the product will decompose in real-world conditions in different climates and hopes to have the data to make a "consumer-facing claim" by next year. It also plans to experiment with plastic-eating fungi on adult diapers, feminine care products and other now, it is selling "diaper bundles" for $35 a week online. Co-founder Miki Agrawal, who was also behind period underwear company Thinx, said the MycoDigestible Diapers had been generating excitement from consumers and investors since launching about a month ago, declining to give details. Agrawal said the company had chosen to focus on diapers as the top household plastic waste item."There is a deleterious lasting effect that we haven't really thought about and considered," Agrawal said. "Because when you throw something away, no one's asking themselves, 'Where's away?'"
